| HOME >> BIOLOGY >> TECHNOLOGY |
Total liabilities 1,837,350 1,535,435
Commitments and Contingencies
Stockholders' Equity
Preferred stock, authorized 5,000,000 shares,
$.01 par value, none issued or outstanding - -
Common stock, authorized 100,000,000 shares,
$.001 par value, 41,130,270 and 40,991,385
issued and outstanding as of June 30, 2008,
and December 31, 2007, respectively 41,130 40,991
Additional paid-in capital 70,601,489 69,945,666
Accumulated deficit (61,940,977) (57,834,638)
Total stockholders' equity 8,701,642 12,152,019
$10,538,992 $13,687,454
SCOLR Pharma, Inc.
CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)
Three months ended Six months ended
June 30, June 30,
2008 2007 2008 2007
Revenues
Licensing fees $- $- $- $173,077
Royalty income 279,571 422,056 545,126 747,676
Research and
development income - - - 621,222
Total revenues 279,571 422,056 545,126 1,541,975
Operating expenses
Marketing and selling 191,047 225,374 428,739 475,256
Research and
development 1,197,321 1,377,499 2,080,533 3,173,374
General and
administrative 1,062,646 1,112,244 2,294,930 2,288,742
Total operating
expenses 2,451,014 2,715,11
'/>"/>
| SOURCE SCOLR Pharma, Inc. Copyright©2008 PR Newswire. All rights reserved |